Global ADHD Therapeutics Market To grow at 7.7% CAGR from 2023 to 2030.


The Global ADHD Therapeutics Market is estimated to be worth USD 14.70 Billion in 2022 and is projected to reach a value of USD 26.61 Billion by 2030, growing at a fast compound annual growth rate (CAGR) of 7.7% during the forecast period 2023-2030. 

The outbreak of the COVID-19 pandemic substantially impacted the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market. The implementation of strict lockdowns, traveling restrictions, and social distancing measures across several nations hindered many companies' manufacturing capacities and caused a shortage of skilled workforce. The pandemic caused disruptions in supply chains and distribution of goods and services, which highly affected the production and distribution of ADHD medications to diagnosed individuals. This led to delayed diagnosis and treatment for ADHD. Moreover, the increased stress among ADHD-diagnosed individuals due to the uncertainty of the COVID-19 pandemic and the economic impact caused by it further worsened the demand for ADHD medications. These factors negatively impacted the growth of the global ADHD therapeutics market. Despite these challenges, the global ADHD therapeutics market is projected to recover and grow in the coming years.

The rising incidence of ADHD among children is fueling the growth of the global ADHD therapeutics market. ADHD-diagnosed children have a higher risk of developing several other disorders and even clinical depression. These children are at risk of developing mental illnesses that last a lifetime due to their skewed lifestyle and inability to control their impulses. Thus, it is essential to come up with effective ADHD treatments for pediatrics. Therefore, this factor drives the demand for ADHD therapeutics. In addition, the rising research and development activities for the treatment of ADHD are another factor contributing to the growth of the global ADHD therapeutics market. The development of new ADHD treatment medications not only increases the efficacy level but also offers ADHD-diagnosed individuals alternative treatment options for whom the currently available medications may not be much effective. Therefore, this factor also drives the demand for ADHD Therapeutics. 

The global ADHD therapeutics market is encountering challenges, primarily in terms of the high cost of ADHD treatment medications and the limited access to ADHD treatment medications in underdeveloped countries. ADHD treatment medications can be expensive depending upon the medication's efficacy, which can restrict the purchase and use of these medications among lower-income individuals. Moreover, access to ADHD treatment medications in underdeveloped countries can be limited due to the lack of healthcare infrastructure and limited distribution networks. Thus, these challenges inhibit the growth of the global ADHD therapeutics market. 

Key Market Insights:

  • Based on the drug type, the global ADHD therapeutics market is segmented into stimulants and non-stimulants. Further, the stimulants segment is bifurcated into amphetamine, methylphenidate, dextroamphetamine, dexmethylphenidate, and lisdexamfetamine dimesylate. The non-stimulants segment is bifurcated into atomoxetine, bupropion, guanfacine, and clonidine. In 2022, the stimulants segment held the highest market share. The growth can be attributed to the stimulants being the most commonly prescribed medication by doctors for the treatment of ADHD. Stimulants, such as atomoxetine, bupropion, and guanfacine, have been used for the longest time for treating ADHD as they are proven to have high efficacy. The stimulants increase the level of dopamine, a neurotransmitter, in the brain, which is linked to focus, motivation, pleasure, and movement. 
  • In 2022, the adolescent segment held the highest market share. The growth can be attributed to the ADHD diagnosis being more common in children than adults. The ADHD symptoms start before the age of 12 years, and in some children, the symptoms are noticeable as early as 3 years of age. However, in recent years, ADHD diagnosis among adults is rising four times more than that among children due to several factors, including the persistence of childhood ADHD, changing societal and environmental factors, and increased access to healthcare regarding ADHD treatment. These factors account for it to be the fastest-growing segment during the forecast period.
  • In 2022, the retail pharmacies segment held the highest market share. The growth can be attributed to retail pharmacies being the most popular medium as a result of the ease of access and widespread availability of ADHD medications. 
  • In 2022, the region of North America held the largest market share. The growth can be attributed to the high rates of ADHD diagnosis and treatment in North American countries, mainly the United States. The increasing prevalence of ADHD among adults and the expansion of the biopharmaceutical industry in the creation of novel treatments further propel the region's growth.
  • Curemark LLC, Adlon Therapeutics L.P, Noven Pharmaceuticals, Inc., Pfizer Inc., Supernus Pharmaceuticals, Inc., Neos Therapeutics, Inc., Novartis AG, Shire plc, Alcobra Ltd., and Johnson & Johnson are among the major players in the global ADHD therapeutics market. The ADHD therapeutics market is estimated to become more competitive as new players enter the industry. Due to their innovation and new product development in the ADHD therapeutics market, Curemark LLC, Adlon Therapeutics L.P, and Noven Pharmaceuticals, Inc. currently dominate the market.


By Drug Type:

  • Stimulants
    • Amphetamine
    • Methylphenidate
    • Dextroamphetamine
    • Dexmethylphenidate
    • Lisdexamfetamine Dimesylate
  • Non-Stimulants
    • Atomoxetine
    • Bupropion
    • Guanfacine
    • Clonidine

By Age Group:

  • Adolescent
  • Adults

By Distribution Channel:

  • E-Commerce
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Clinics

By Region:

  • North America 
  • Europe 
  • Asia Pacific
  • Rest of the World

Request Sample Copy of this Report @

Analyst Support

Every order comes with Analyst Support


We offer customization to cater your needs to fullest

Verified Analysis

We value Integrity, quality and authenticity the most